Skip to main content
BIODYNE CO., LTD. logo

BIODYNE CO., LTD. — Investor Relations & Filings

Ticker · 314930 ISIN · KR7314930009 KO Manufacturing
Open in API
Filings indexed 118 across all filing types
Latest filing 2026-05-15 Major Shareholding Noti…
Country KR South Korea
Listing KO 314930

About BIODYNE CO., LTD.

https://biodyne.co.za/

BIODYNE CO., LTD. is a developer and manufacturer of medical devices, reagents, and consumables specializing in cancer diagnosis solutions. The company's core offering is the PATHPLORER Liquid-Based Cytology (LBC) system, which includes fully automatic cell preparation instruments and associated diagnostic kits. A key differentiator is its patented 'Blowing Technology,' a unique method for cell preparation in LBC diagnostics, which the company pioneered. BIODYNE focuses on providing advanced solutions for cytopathology to improve the accuracy and efficiency of disease screening.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a statutory ‘Report on Large Shareholding’ under Korea’s Capital Market Act, detailing the number of shares held by the major shareholder and related parties, the reasons for changes, and breakdowns of holdings. This matches the Major Shareholding Notification category.
2026-05-15 Korean
기업설명회(IR)개최
Investor Presentation Classification · 80% confidence The document is a notice of a corporate investor relations event (“기업설명회(IR) 개최”), detailing date, time, location, purpose, method (Non-Deal Roadshow), agenda, sponsor, and IR materials posting. This fits the definition of an Investor Presentation announcement rather than an earnings release or proxy statement. Therefore, the appropriate category is Investor Presentation (IP).
2026-05-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled "분기보고서" covering the period 2026-01-01 to 2026-03-31 (the first quarter) and contains detailed financial tables, business overview, product lines, capital movements, sales breakdowns, production and sales strategies, risk management, etc. It is a full quarterly financial report (with substantive financial data and narrative) rather than a brief earnings release or announcement. Therefore, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
[기재정정]정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a disclosure of the Annual General Meeting (정기주주총회) results, detailing each agenda item, voting percentages, and outcomes, including a correction notice to revise the approval rate on the director compensation limit. This precisely matches a Declaration of Voting Results & Voting Rights Announcement.
2026-03-24 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a report of the Annual General Meeting held on 2026-03-23, detailing the approval of financial statements, dividend resolutions, board appointments, voting record date, and detailed vote results (approval status, vote percentages) for each agenda item. This corresponds to the declaration of voting results following a shareholders’ meeting.
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by the company Biodine. It contains the auditor's opinion (적정 - unqualified), financial statements (assets, liabilities, equity, revenue, profit/loss), and details regarding the audit process. This is a standard regulatory filing in Korea (DART system) that provides the results of the annual audit, which falls under the 'Audit Report / Information' category. FY 2025
2026-03-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.